2026 AACR Prostate Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from AACR 2026. Highlights in this video include: • 225Ac-J591 showed that fractionated PSMA-targeted alpha therapy appears more feasible than multiple-cycle dosing, with encouraging PSA, CTC/RECIST, PFS, and OS signals, although hematologic toxicity- especially thrombocytopenia remains the key limiting factor. • CBP/p300 inhibition plus PARP inhibition provides a compelling preclinical synthetic lethality strategy in advanced prostate cancer potentially supporting future biomarker-driven early-phase trials.